Trigeminal schwannoma

Summary

Trigeminal schwannoma (MONDO:0002555) is a disease. A subtype of trigeminal nerve neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	trigeminal schwannoma
Mondo ID	MONDO:0002555
DOID	DOID:3202
NCIT	C4655
SNOMED CT	277185000
UMLS	C0349582
MedGen	83890
GARD	0023165
Anatomy (UBERON)	UBERON:0001645
Is cancer (heuristic)	no

Also known as: fifth cranial nerve neurilemmoma · fifth cranial nerve schwannoma · neurilemmoma of fifth cranial nerve · neurilemmoma of the fifth cranial nerve · neurilemmoma of the trigeminal nerve · neurilemmoma of trigeminal nerve · schwannoma of fifth cranial nerve · schwannoma of the fifth cranial nerve · schwannoma of the trigeminal nerve · schwannoma of trigeminal nerve · trigeminal nerve schwannoma · trigeminal neurilemmoma · trigeminal schwannoma

Disease family

This is a subtype of trigeminal nerve neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral nervous system neoplasm › cranial nerve neoplasm › trigeminal nerve neoplasm › trigeminal schwannoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.